These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 12840712)

  • 1. Are SSRIs safe for children?
    Med Lett Drugs Ther; 2003 Jul; 45(1160):53-4. PubMed ID: 12840712
    [No Abstract]   [Full Text] [Related]  

  • 2. Obsessive-compulsive spectrum disorders: effective treatment with paroxetine.
    Ravindran AV; Lapierre YD; Anisman H
    Can J Psychiatry; 1999 Oct; 44(8):805-7. PubMed ID: 10566112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paroxetine. An update of its pharmacology and therapeutic use in depression and a review of its use in other disorders.
    Gunasekara NS; Noble S; Benfield P
    Drugs; 1998 Jan; 55(1):85-120. PubMed ID: 9463792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder.
    Denys D; van der Wee N; van Megen HJ; Westenberg HG
    J Clin Psychopharmacol; 2003 Dec; 23(6):568-75. PubMed ID: 14624187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amotivational syndrome associated with selective serotonin reuptake inhibitors in children and adolescents.
    Garland EJ; Baerg EA
    J Child Adolesc Psychopharmacol; 2001; 11(2):181-6. PubMed ID: 11436958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Differential features of SSRIs].
    Cervera S
    Rev Med Univ Navarra; 1997; 41(4):245-57. PubMed ID: 10420965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Obsessive-compulsive disorder: implications of the efficacy of an SSRI, paroxetine.
    Ninan PT
    Psychopharmacol Bull; 2003; 37 Suppl 1():89-96. PubMed ID: 14566204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Selective serotonin reuptake inhibitor(SSRI)].
    Motohashi N
    Nihon Rinsho; 2001 Aug; 59(8):1519-22. PubMed ID: 11519151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Safety of selective serotonin reuptake inhibitor antidepressants in children and adolescents].
    Bailly D
    Presse Med; 2006 Oct; 35(10 Pt 2):1507-15. PubMed ID: 17028514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Selective serotonin reuptake inhibitors in treatment of compulsive symptoms within the scope of schizophrenia].
    Scholl HP; Kasper S; Danos P; Höflich G; Möller HJ
    Nervenarzt; 1994 Jul; 65(7):478-81. PubMed ID: 7800092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive-compulsive disorder: a single-blind study.
    Mundo E; Bianchi L; Bellodi L
    J Clin Psychopharmacol; 1997 Aug; 17(4):267-71. PubMed ID: 9241005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluvoxamine: new indication. No progress in obsessive-compulsive disorder.
    Prescrire Int; 2004 Oct; 13(73):163-5. PubMed ID: 15499694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paroxetine open-label treatment of pediatric outpatients with obsessive-compulsive disorder.
    Rosenberg DR; Stewart CM; Fitzgerald KD; Tawile V; Carroll E
    J Am Acad Child Adolesc Psychiatry; 1999 Sep; 38(9):1180-5. PubMed ID: 10504818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of comorbidity on treatment response to paroxetine in pediatric obsessive-compulsive disorder: is the use of exclusion criteria empirically supported in randomized clinical trials?
    Geller DA; Biederman J; Stewart SE; Mullin B; Farrell C; Wagner KD; Emslie G; Carpenter D
    J Child Adolesc Psychopharmacol; 2003; 13 Suppl 1():S19-29. PubMed ID: 12880497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paroxetine response and tolerability among ethnic minority patients with mood or anxiety disorders: a pooled analysis.
    Roy-Byrne PP; Perera P; Pitts CD; Christi JA
    J Clin Psychiatry; 2005 Oct; 66(10):1228-33. PubMed ID: 16259535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine.
    Hollander E; Allen A; Steiner M; Wheadon DE; Oakes R; Burnham DB;
    J Clin Psychiatry; 2003 Sep; 64(9):1113-21. PubMed ID: 14628989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paroxetine treatment in children and adolescents with obsessive-compulsive disorder: a randomized, multicenter, double-blind, placebo-controlled trial.
    Geller DA; Wagner KD; Emslie G; Murphy T; Carpenter DJ; Wetherhold E; Perera P; Machin A; Gardiner C
    J Am Acad Child Adolesc Psychiatry; 2004 Nov; 43(11):1387-96. PubMed ID: 15502598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paroxetine in the treatment of obsessive-compulsive disorder: randomized, double-blind, placebo-controlled study in Japanese patients.
    Kamijima K; Murasaki M; Asai M; Higuchi T; Nakajima T; Taga C; Matsunaga H
    Psychiatry Clin Neurosci; 2004 Aug; 58(4):427-33. PubMed ID: 15298657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study.
    Pallanti S; Quercioli L; Bruscoli M
    J Clin Psychiatry; 2004 Oct; 65(10):1394-9. PubMed ID: 15491244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. OCD Paroxetine Study Investigators.
    Zohar J; Judge R
    Br J Psychiatry; 1996 Oct; 169(4):468-74. PubMed ID: 8894198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.